Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Diabetes Mellitus, Type 2, Heart Failure...
Phase PHASE4
Enrollment 17200
Locations 12 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this clinical trial is investigate the comparative effectiveness of empagliflozin and dapagliflozin for the treatment of diabetes, chronic kidney disease, and heart failure. Patients who are prescribed either empagliflozin or dapagliflozin, as part of daily clinical practice at the participating sites, will be included in the study. Treatment will be randomized automatically through the electronic health record software in clusters defined by time of day. https://www.appletreestudy.com

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Empagliflozin 10 MG — Once daily
  • Drug: Dapagliflozin 10 MG — Once daily

Primary Outcomes

  • Time to the first occurrence of any of the components of the composite: all-cause mortality, hospitalization for heart failure, hospitalization for myocardial infarction, hospitalization for ischemic stroke, and incident or worsening nephropathy. (Up to 24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2024-10-10
Completion: 2028-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 17200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Herlev and Gentofte Hospital
Contact Information
Study Contact:
Morten Schou, Professor
004540523920
morten.schou.04@regionh.dk
Daniel M. Christensen, MD, PhD
004526248546
dmc@dadlnet.dk
Morten Schou, Professor
004540523920
morten.schou.04@regionh.dk
Herlev and Gentofte Hospital
Interventions
  • Drug: Empagliflozin 10 MG — Once daily
  • Drug: Dapagliflozin 10 MG — Once daily
Study Locations (12 sites)
Bispebjerg Hospital, Copenhagen, Denmark
Rigshospitalet, Copenhagen, Denmark
Herlev and Gentofte Hospital, Herlev, Denmark
Steno Diabetes Center Copenhagen, Herlev, Denmark
Nordsjællands Hospital, Hillerød, Denmark
Holbæk Sygehus, Holbæk, Denmark
Hvidovre Hospital, Hvidovre, Denmark
Sjællands Universitetshospital, Køge, Denmark
Nykøbing F. Sygehus, Nykøbing Falster, Denmark
Sjællands Universitetshospital, Roskilde, Denmark
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 years or more Exclusion Criteria: * Incapabability of giving informed consent * Withdrawal of informed consent

Agnostic Therapy in Rare Solid Tumors

NCT06638931
Recruiting
Conditions Urachal Cancer, Parathyroid Carcinoma, F...
Phase PHASE2
Enrollment 28
Locations 8 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The ANTARES study is a phase II basket trial designed to evaluate the tissue-agnostic efficacy of the monoclonal anti-PD1 antibody, nivolumab, in patients with advanced or metastatic rare tumors. The study aims to treat rare malignancies with PD-L1 expression (CPS ≥ 10), regardless of the tumor's tissue type or location. Patients who have not responded to standard treatments will be included, and treatment will last for up to 12 months. The study will assess objective response, progression-free survival, and biomarkers such as PD-L1, ctDNA, and microvesicles, in a multicenter collaborative effort to provide innovative therapeutic options for this underrepresented population

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Nivolumab — The intervention consists of administering Nivolumab 480 mg intravenously every 4 weeks, with a +5 day window for postponement but not for advancement of treatment. Treatment will continue until limiting toxicity, disease progression, or for a maximum period of 12 months (13 cycles) as maintenance therapy, provided the patient maintains stable disease, a partial response, or a complete response. Patients who are off treatment for more than 56 days (2 cycles) due to Nivolumab-related toxicities or other clinical issues will be discontinued from the protocol. After 12 months of treatment or in the event of study discontinuation for any reason, patients will be followed by the research team via telephone every 60 days, with a +/- 7 day window, until death.

Primary Outcomes

  • Primary Objective (2 years)
  • Primary Endpoint (2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-07-16
Completion: 2028-05
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 28 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Instituto do Cancer do Estado de São Paulo
Collaborators: Financiadora de Estudos e Projetos
Principal Investigators:
  • Camila MV Moniz, Doctor (PRINCIPAL_INVESTIGATOR) - Oncologist
Contact Information
Study Contact:
Camila MV Moniz, Doctor
+ 55 11 3893-3925
camila.venchiarutti@hc.fm.usp.br
Raelson Miranda, Doctor
+ 55 11 3893-3566
raelson.m@hc.fm.usp.br
Karine M Trindade
+55 85 3257-9408
regulatorio.idor@rededor.com.br
Hospital São Carlos
Interventions
  • Drug: Nivolumab — The intervention consists of administering Nivolumab 480 mg intravenously every 4 weeks, with a +5 day window for postponement but not for advancement of treatment. Treatment will continue until limiting toxicity, disease progression, or for a maximum period of 12 months (13 cycles) as maintenance therapy, provided the patient maintains stable disease, a partial response, or a complete response. Patients who are off treatment for more than 56 days (2 cycles) due to Nivolumab-related toxicities or other clinical issues will be discontinued from the protocol. After 12 months of treatment or in the event of study discontinuation for any reason, patients will be followed by the research team via telephone every 60 days, with a +/- 7 day window, until death.
Study Locations (8 sites)
Hospital São Carlos, Fortaleza, Ceará 60170-170 Brazil
Hospital São Rafael, Salvador, Estado de Bahia 41253-190 Brazil
Hospital Santa Cruz, Curitiba, Paraná 80420-090 Brazil
IDOR Recife, Recife, Pernambuco 52010-010 Brazil
Instituto D'or de Pesquisa e Ensino, São Paulo, São Paulo 04.501-000 Brazil
Instituto do Câncer do Estado de São Paulo - ICESP, São Paulo, São Paulo 05403-010 Brazil
DF Star, Brasília, 70390-903 Brazil
Instituto D'Or de Pesquisa e Ensino, Rio de Janeiro, 22281-100 Brazil
Eligibility Criteria
Inclusion Criteria 1. Age 18 years or older. 2. Patients with immunohistochemistry for PD-L1 with a combined positive score (CPS) of 10 or higher. 3. Patients with progression or intolerance to already approved and accessible treatments for the specific neoplasm and population. 4. Documented disease progression radiologically after the last routine treatment. 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 6. Measurable lesion per RECIST v1.1. Lesions previously treated with radiotherapy can only be used as target lesions if they are confirmed to be progressing by imaging before enrollment. 7. Male participants must meet at least one of the following conditions: 1. Considered infertile; 2. No fertile partner; 3. Has a fertile partner who agrees to follow contraceptive guidance throughout the study period and for at least 6 months after the last dose of Nivolumab; and 4. Agrees to abstain from sperm donation throughout the study period and for at least 6 months after the last dose of Nivolumab. 8. Female participants must meet at least one of the following conditions: 1. Considered infertile; 2. Agrees to follow contraceptive guidance throughout the study period and for at least 6 months after the last dose of Nivolumab; 9. Estimated life expectancy greater than 12 weeks, as determined by the investigator or delegated sub-investigator. 10. Preserved organ functions defined by: * Absolute neutrophil count ≥ 1,000; * Hemoglobin ≥ 8.0 g/dL (patients may receive transfusions to reach this level); * Platelet count ≥ 100,000; * Total bilirubin ≤ 1.5 × Upper Limit of Normal (ULN), or ≤ 3.0 × ULN for patients with Gilbert's syndrome; * Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤ 2.5 × ULN (≤ 5 × ULN in the presence of liver metastases); * Creatinine clearance \> 30 mL/min (estimated by Cockcroft-Gault). 11. Diagnosis of rare cancer (List I) confirmed by histopathological examination, with the possibility of including other types of rare tumors (incidence of less than 6 in every 100,000) after careful evaluation and approval by the study board. * List I: * Urachal adenocarcinoma * Parathyroid carcinoma * Nasopharyngeal epithelial tumors * Fibrolamellar carcinoma of any primary site * Angiosarcoma of any primary site * Secretory breast carcinoma * Anal cancer * Metaplastic breast carcinoma * Chromophobe renal carcinoma, Microphthalmia-associated Transcription Factor (MiT) family translocation renal carcinoma; renal carcinoma with Fumarate Hydratase (FH) or Succinate Dehydrogenase (SDH) deficiency * Carcinosarcoma of any primary site * Small intestine cancer * Cholangiocarcinoma * Sertoli-Leydig cell tumors * Cervical cancer of non-epidermoid histology * Tracheal epithelial tumors * Non-cystadenoma salivary gland tumors * Mesothelioma of any site * Neuroblastoma * Adrenal cancer * Penile cancer * Apocrine carcinoma * Fibrosarcoma of any primary site * Cancer of unknown primary site * Hemangioblastoma of any primary site * Thyroid cancer * Hepatoblastoma * Fallopian tube cancer * Leiomyosarcoma of any primary site * Vaginal cancer * Neurofibrosarcoma of any primary site * Gallbladder cancer * Osteosarcoma of any primary site * Bile duct cancer * Clear cell endometrial carcinoma * Yolk sac tumor of any primary site * Non-epidermoid bladder cancer * Vulvar cancer * Kaposi's sarcoma * Epithelial ovarian cancer * Soft tissue sarcoma * Urethral cancer * Granulosa cell tumor of any primary site * Cystadenoma carcinoma * Primitive neuroectodermal tumor of any primary site * Pure or mixed neuroendocrine tumors with neuroendocrine component * Trophoblastic tumor Exclusion Criteria 1. Previous treatment lines with immunotherapy (immune checkpoint inhibitors). 2. Pregnant or breastfeeding individuals. 3. Limiting comorbidity, in the opinion of the investigator. 4. Active infection. 5. Major surgery within the last 4 weeks. 6. Functional class II or greater heart failure. 7. Myocardial infarction or stroke within the last 6 months. 8. History of pulmonary fibrosis or pneumonitis. 9. Autoimmune diseases, except for patients with vitiligo and/or controlled thyroid/hypothyroidism without the use of immunosuppressors. 10. Second invasive primary tumor diagnosed in the last 3 years and/or with active disease, except for localized skin tumors (non-melanoma) that have been treated with curative intent. 11. Patients with prolonged QT interval. 12. Uncontrolled Central Nervous System (CNS) metastases. Patients who have previously received local treatment, such as radiotherapy, will be eligible if clinical and radiological stability is demonstrated in the 2 weeks prior to the start of treatment. Patients must not be using corticosteroids for managing CNS disease. 13. Presence of meningeal carcinomatosis. 14. Worsening renal and liver function in the 14 days prior to enrollment. 15. History of solid organ transplantation with or without immunosuppression. 16. Patients with untreated acquired immunodeficiency. Immunocompromised patients may be included as long as they do not have active opportunistic disease and/or active infection, after thorough clinical evaluation by the investigator or sub-investigator. HIV-positive patients must have documented undetectable viral load prior to inclusion. 17. Chronic use of corticosteroids at doses greater than 10 mg/day of prednisone or equivalent. Patients with adrenal insufficiency of non-autoimmune etiology (e.g., previous bilateral adrenalectomy) may be included if they are clinically compensated with 10 mg/day of prednisone or equivalent or less.
Conditions Lung Cancers, Liver Cancer, Gastric Canc...
Phase NA
Enrollment 1000000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Cancer poses a major public health challenge in China. Early detection can improve treatment outcomes and survival rates. In this study, we will conduct a large-scale, prospective, multi-center cohort study to evaluate the utility of AI-assisted non-contrast CT for multi-cancer screening. The study aims to enroll 1 million asymptomatic participants undergoing routine health examinations, using an AI imaging model based on non-contrast CT to detect seven cancers such as lung, liver, gastric, colorectal, esophageal, pancreatic, and breast cancers. Positive cases will be required to be referred to Shanghai Changhai Hospital for further imaging and care based on National Comprehensive Cancer Network (NCCN) and American College of Radiology (ACR) guidelines. The goal is to assess the AI model's diagnostic performance for seven cancer types, especially for early-stage, resectable tumors.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: AI-Assisted Non-Contrast CT for Multi-Cancer Screening — Participants identified by the AI model as having potential cancerous lesions, including those suspected of lung, liver, gastric, colorectal, esophageal, pancreatic, and breast cancer, will be required to undergo blood tests (for tumor markers) and additional imaging studies (such as contrast-enhanced CT, MRI, Endoscopy, etc.) to confirm the diagnosis of cancerous lesions.

Primary Outcomes

  • Diagnostic yield (3 years)
  • Incidence (3 years)
  • Resectable rate (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-10-07
Completion: 2027-10-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 1000000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Guo ShiWei
Principal Investigators:
  • Jin Gang, M.D. (STUDY_CHAIR) - Department of general surgery, Changhai Hospital
Contact Information
Study Contact:
Wang Beilei, M.D.
86-13774238083
lilly_wang@126.com
Guo Shiwei, M.D.
86-18621500666
gestwa@163.com
Wang Beilei, M.D.
86-13774238083
lilly_wang@126.com
Changhai Hospital
Interventions
  • Diagnostic Test: AI-Assisted Non-Contrast CT for Multi-Cancer Screening — Participants identified by the AI model as having potential cancerous lesions, including those suspected of lung, liver, gastric, colorectal, esophageal, pancreatic, and breast cancer, will be required to undergo blood tests (for tumor markers) and additional imaging studies (such as contrast-enhanced CT, MRI, Endoscopy, etc.) to confirm the diagnosis of cancerous lesions.
Study Locations (1 sites)
Changhai Hospital, Shanghai, Shanghai Municipality 200433 China
Eligibility Criteria
Inclusion Criteria: 1. Subject is able and willing to provide informed consent and sign an informed consent form. 2. Subject has undergone an abdominal or chest non-contrast CT scan. Exclusion Criteria: 1. Subject has been diagnosed with one of the following cancers within the last five years: lung, liver, stomach, colon, esophageal, pancreatic, or breast cancer; 2. Subject has any medical condition that contraindicates high-resolution MRI/CT/Endoscopy; 3. Subject cannot be followed up or is participating in other clinical trials.
Conditions Type II Diabetes Mellitus
Phase NA
Enrollment 240
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This project aims to adapt, implement, and evaluate PLA based intervention in urban Karachi, Pakistan for TIIDM prevention and control.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Participatory, learning and Action (PLA) Based intervention — An PLA based intervention would be carried out to prepare the Diabetes Mellitus type II patients. The intervention would be carried out for a tentative time of 2 to 3 hours to educate the type II diabetes mellitus. The study participants would be evaluated after completion of 18 months of the intervention. A structured, validated and literature-based assessment checklist will be devised to assess the effectiveness and feasibility of the intervention.

Primary Outcomes

  • Prevalence of Type II Diabetes Mellitus (18 months)
  • Two-year cumulative incidence of Type II Diabetes Mellitus (18 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-06-24
Completion: 2027-10
Eligibility
Age: 20 Years and older
Sex: ALL
Volunteers: true
Enrollment: 240 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Baqai Institute of Diabetology and Endocrinology
Collaborators: University of York, Khyber Medical University Peshawar, HealthNet TPO, National Institute for Health Research, United Kingdom, Aga Khan University Hospital, Pakistan
Principal Investigators:
  • Abdul Basit, Director (PRINCIPAL_INVESTIGATOR) - Baqai Institute of Diabetes and Endocrinology
Contact Information
Study Contact:
Abdul Basit, Director
922136688897
abdulbasit@bide.edu.pk
Rubia Zafar, TrialManager
rzafar@bide.edu.pk
Rubia Zafar, TrialManager
922136688897
rzafar@bide.edu.pk
Baqai Institute of Diabetology and Endocrinology (BIDE)
Interventions
  • Behavioral: Participatory, learning and Action (PLA) Based intervention — An PLA based intervention would be carried out to prepare the Diabetes Mellitus type II patients. The intervention would be carried out for a tentative time of 2 to 3 hours to educate the type II diabetes mellitus. The study participants would be evaluated after completion of 18 months of the intervention. A structured, validated and literature-based assessment checklist will be devised to assess the effectiveness and feasibility of the intervention.
Study Locations (1 sites)
Baqai Institute of Diabetology and Endocrinology (BIDE), Karachi, Sindh 74600 Pakistan
Eligibility Criteria
Inclusion Criteria: * Individuals aged 20 years and above. * Participants residing in the randomized clusters of Karachi, Pakistan * Individuals willing to participate in the study and provide consent. * Both individuals with normoglycemia, intermediate hyperglycemia, and diabetes are encouraged to participate. * Participants who can attend the scheduled meetings and interventions as per the study protocol. Exclusion Criteria: * Individuals below the age of 20 years. * Individuals unwilling to provide consent for participation. * Participants with severe health conditions that may hinder their active involvement in the study. * Individuals with non-compliance with research protocols
Conditions Pain, Anxiety
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This case control study will be conducted to study the effectiveness of Virtual Reality technique on pain during arteriovenous cannulation and on reduction of anxiety and depression in Pediatric Patients with ESRD undergoing regular hemodialysis through arteriovenous fistula.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Double

Interventions / Regimen

  • Other: virtual reality camera — The virtual reality eyeglasses were placed on the child's head, the child watched 3 D VR kids' cartoons or videos to distract his/her attention during needle insertion. The video was displayed through a smart phone inserted inside the virtual reality headset.

Primary Outcomes

  • SCARED for anxiety Screen for Child Anxiety Disoders {SCARED} Child, parent version: It is a self-report screening questionnaire for anxiety disorders during hemodialysis (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-04-01
Completion: 2024-11-30
Eligibility
Age: 8 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tanta University
Principal Investigators:
  • sara Ma ElGhoul, MD (PRINCIPAL_INVESTIGATOR) - Tanta university hospital
Contact Information
Study Contact:
Sara Ma ElGhoul, MD
01099204120
sara.mabrouk@med.tanta.edu.eg
sara mabrouk lecturer of pediatrics, MD
01099204120
sara.mabrouk@med.tanta.edu.eg
Tanta University Hospital
Interventions
  • Other: virtual reality camera — The virtual reality eyeglasses were placed on the child's head, the child watched 3 D VR kids' cartoons or videos to distract his/her attention during needle insertion. The video was displayed through a smart phone inserted inside the virtual reality headset.
Study Locations (1 sites)
Tanta University Hospital, Tanta, 31527 Egypt
Eligibility Criteria
Inclusion Criteria: * Pediatric patients with end stage renal disease aged from 8 to 18 years on regular hemodialysis through functioning arteriovenous fistula and are fully oriented with time, persons and place at time of data collection. All participants either cases or controls suffer from anxiety, depression or both. Exclusion Criteria: * Children with temporary or permanent catheter for dialysis. * Children with mental illness, visual and auditory defects. * Children took any pharmacological pain reliever or antipsychotic drugs. * Non anxious or depressed Children.
Conditions CCCA Assessed by Ki67 Drop Below <2.7% F...
Phase PHASE2
Enrollment 120
Locations 25 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a multicenter, prospective, open-label, randomized phase II study to evaluate the CCCA assessed by Ki67 drop below \&lt;2.7% from baseline to week 2 (window of opportunity) and to week 10 with capivasertib plus fulvestrant compared with fulvestrant alone as neoadjuvant treatment for primary high-risk lobular breast cancer patients. 120 patients will be randomized to receive: \- Capivasertib (400 mg po twice daily d1-4 followed by 3 days off) for 2 weeks followed by capivasertib (400 mg po twice daily d1-4 followed by 3 days off) and fulvestrant (500 mg i.m. q28d, with an additional 500 mg dose given two weeks after the initial dose) for additional 8 weeks (overall 4 administrations of fulvestrant) or \- Fulvestrant (500mg i.m. q28d, with an additional 500 mg dose given two weeks after the core biopsy and the initial dose) for 10 weeks (overall 4 administrations) Treatment will be given until surgery/core-biopsy, disease progression, unacceptable toxicity, or withdrawal of consent of the patient. All patients will undergo core-biopsies, under treatment and after completing study therapy in order to assess Ki67%. Further treatment including surgery, (neo)adjuvant chemotherapy, radiotherapy, and (neo)adjuvant endocrine therapy will be administered at the discretion of the investigator and according to standard of care outside the clinical trial.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Capivasertib — find arm A description
  • Drug: Fulvestrant injection — find arm B description

Primary Outcomes

  • To assess complete cell cycle arrest (CCCA). (Up to 14 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-12-04
Completion: 2026-08-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: GBG Forschungs GmbH
Collaborators: AstraZeneca
Principal Investigators:
  • Sibylle Loibl, Prof. Dr. med. (PRINCIPAL_INVESTIGATOR) - ESMO, ASCO, AGO Kommission Mamma (member); Goethe University Frankfurt; GBG Forschungs GmbH
Contact Information
Study Contact:
Christina Müller-Weisbrod
+49610274800
LOBSTER@gbg.de
Heinrich, Dr. med.
+49-821-3446-50
bernhard.heinrich@hop-augsburg.de
Haematologie-Onkologie im Zentrum MVZ GmbH
Steinke, Dr. med.
+49-521-9887-770
siemke.steinke@onkologie-bielefeld.de
Onkologische Schwerpunktpraxis - Studiengesellschaft Onkologie Bielefeld GbR
Interventions
  • Drug: Capivasertib — find arm A description
  • Drug: Fulvestrant injection — find arm B description
Study Locations (25 sites)
Haematologie-Onkologie im Zentrum MVZ GmbH, Augsburg, 86150 Germany
Charité, Berlin, 10117 Germany
Onkologische Schwerpunktpraxis - Studiengesellschaft Onkologie Bielefeld GbR, Bielefeld, 33604 Germany
Hämato-Onkologie im Medicum - Onkologie und Hämatologie, Bremen, 28209 Germany
Kliniken der Stadt Köln GmbH - Brustzentrum Köln-Holweide, Cologne, 51067 Germany
Carl-Thiem-Klinikum gGmbH - Frauenklinik, Cottbus, 03048 Germany
Kath. St. Paulus GmbH - Klinische Forschung, Dortmund, 44137 Germany
Universitätsklinikum Essen - Klinik für Frauenheilkunde und Geburtshilfe, Essen, 45147 Germany
Klinikum Frankfurt Höchst GmbH - Klinik für Gynäkologie und Geburtshilfe, Frankfurt am Main, 65929 Germany
Praxis für Interdisziplinäre Onkologie & Hämatologie, Freiburg im Breisgau, 79110 Germany
Eligibility Criteria
Inclusion Criteria: 1. Written informed consent prior to beginning specific protocol procedures, including expected cooperation of the patients for the treatment and followup, and documented according to the local regulatory requirements. 2. Postmenopausal women with age at diagnosis ≥ 18 years. Postmenopausal status is defined as: * Age ≥60 years * Age \<60 years and amenorrhea for at least 12 continuous months with no identified cause other than menopause * Bilateral oophorectomy Negative pregnancy test (urine or serum) within 14 days prior to randomization for all postmenopausal women 50 years of age or younger without bilateral oophorectomy 3. Unilateral or bilateral primary untreated lobular invasive carcinoma of the breast. In case of bilateral breast cancer, both sides must be lobular; the lead tumor has to be defined by the investigator based on the inclusion criteria for the respective subtype and the risk status. Lobular histology has to be centrally confirmed. 4. Willingness and ability to provide archived formalin fixed paraffin embedded (FFPE) tissue block from core biopsy before the start of neoadjuvant therapy. 5. Centrally confirmed HER2-negative (IHC score 0-1+ or ISH negative according to ASCO/CAP guideline) and HR-positive (≥10% positive stained cells) disease, assessed on the core of diagnostic biopsy. Ki67% \>10% is required. In case of bilateral breast cancer, HER2-negative, HR-positive and lobular histology status has to be confirmed for both sides. 6. Patients with invasive lobular breast cancer at high risk for recurrence defined as cT1c and clinical nodal involvement (cN+) or ≥ cT2 disease (irrespective of nodal involvement). 7. No clinical evidence of distant metastases. 8. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1. 9. Estimated life expectancy of at least 5 years irrespective of the diagnosis of breast cancer. 10. The patient must be accessible for scheduled visits, treatment, and followup. 11. Normal cardiac function must be confirmed according to local guidelines. 12. Laboratory requirements: Hematology * Absolute neutrophil count (ANC) ≥1.5 x 109 / L * Platelets ≥100 x 109 / L * Hemoglobin ≥10 g/dL (≥6.2 mmol/L) Hepatic function * Total bilirubin \<1.25x ULN * AST and ALT \<=1.5x ULN * Alkaline phosphatase \<=2.5x ULN Glucose Metabolism * HbA1c \<8.0% (63.9 mmol/mol) Renal Function * Creatinine \<1.25x ULN or creatinine clearance ≥50 ml/min (if creatinine is above ULN according to Cockroft-Gault) 13. Complete staging work-up prior to the initiation of neoadjuvant therapy as per standard recommendations. Exclusion Criteria: 1. Female patients of childbearing potential. 2. Excisional biopsy or lumpectomy performed prior to study entry. 3. Surgical axillary staging procedure including sentinel lymph node biopsy prior to randomization. Exceptions: FNA or core biopsy of an axillary lymph node. 4. Any previous treatment including endocrine therapy, chemotherapy, radiotherapy or targeted therapy (including AKT inhibitor or PIK3 inhibitor) for the currently diagnosed breast cancer. 5. Concurrent use of herbal or natural products intended as treatment or prophylaxis for any type of cancer. 6. Known hypersensitivity reaction to one of the compounds or substances used in this protocol. 7. Potent inhibitors or inducers of CYP3A4 within 2 weeks prior to the first dose of study treatment (3 weeks for St John's wort). 8. Refractory nausea and vomiting, chronic gastrointestinal disease, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption, distribution, metabolism, or excretion of capivasertib. 9. Any contraindication for fulvestrant. 10. Patients with definitive clinical or radiologic evidence of stage IV cancer (metastatic disease) are not eligible. 11. Patients with a history of any malignancy are ineligible with the following exceptions: * Patient has been disease-free for at least 5 years and is at low risk for recurrence of that malignancy except for breast cancer. * CIS of the cervix, basal cell and squamous cell carcinomas of the skin. 12. History of type I or type II diabetes mellitus requiring insulin. 13. Severe and relevant co-morbidity that would interact with the application of study drugs or the participation in the study, including cerebrovascular incident including transient ischemic attack, or symptomatic pulmonary embolism, active infection requiring intravenous anti-microbial treatment (antibiotics, anti-fungal, and anti-viral drugs) within 1 week of enrolment. Patients with confirmed Gilbert's syndrome may be included in the study. 14. Known medically history of HIV infection, tuberculosis, or hepatitis B. 15. History of and/or active cardiac disease that would preclude the use of study treatments. This includes but is not confined to any of the following cardiac criteria: * Clinically significant cardiac dysfunction including heart failure (NYHA II-IV), active ventricular arrhythmias requiring medication or arrhythmias requiring a pacemaker, and history of a myocardial infarction within 6 months prior to randomization, angina pectoris, atrial fibrillation of any grade, coronary/peripheral artery bypass graft, angioplasty, or vascular stent. * Mean resting QT interval corrected by Fridericia's formula (QTcF) \>470 msec obtained from 3 consecutive ECGs. * Increased risk of QTc prolongation or risk of arrhythmic events such as heart failure, uncontrolled electrolyte disorders (e.g., hypocalcemia, hypokalemia, or hypomagnesemia), potential for torsades de pointes, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age, or any concomitant medication known to prolong the QT interval. 16. Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving therapy. 17. History of significant neurological or psychiatric disorders including psychotic disorders, dementia, or seizures that would prohibit the understanding and giving of informed consent. 18. Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results (such as severe or uncontrolled systemic diseases, including uncontrolled hypertension or hypotension (BP \<50mmHg), significant aneurysm, renal transplant and active bleeding diseases). 19. Major surgical procedure (excluding placement of vascular access) or significant traumatic injury within 4 weeks of the first dose of study intervention or an anticipated need for major surgery during the study. 20. Participation in another clinical study with a study intervention or investigational medicinal device administered in the 4 weeks prior to first dose of study intervention or concurrent enrolment in another clinical study unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.
Conditions Advanced Unresectable or Metastatic Brea...
Phase PHASE1, PHASE2
Enrollment 300
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The study is being conducted to evaluate the efficacy, and safety of dexmedetomidine hydrochloride nasal spray for preoperative sedation in adults. To explore the reasonable dosage of dexmedetomidine hydrochloride nasal spray for preoperative sedation.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: HRS-2189 — HRS-2189
  • Drug: Fluvustat — Fluvustat
  • Drug: HRS-8080 — HRS-8080
  • Drug: HRS-6209 — HRS-6209
  • Drug: HRS-1358 — HRS-1358

Primary Outcomes

  • AEs+SAEs (From the first drug administration to within 30 days for the last treatment dose.)
  • Dose limited toxicity (DLT) (Up to 28 days.)
  • Maximum tolerated dose (MTD) (Up to 28 days.)
  • Recommended Phase II Dose (RP2D) (Up to 28 days.)
  • ORR (objective response rate) - Stage II (efficacy expansion) (Every 8 weeks lasting about one year.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2025-01-21
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shandong Suncadia Medicine Co., Ltd.
Contact Information
Study Contact:
Xia Zhang, M.M
+86-0518-81220121
xia.zhang@hengrui.com
Qingyuan Zhang
+86-0451-86298192
13313612989@163.com
Harbin Medical University Affiliated Cancer Hospital
Qingyuan Zhang
Harbin Medical University Affiliated Cancer Hospital
Interventions
  • Drug: HRS-2189 — HRS-2189
  • Drug: Fluvustat — Fluvustat
  • Drug: HRS-8080 — HRS-8080
  • Drug: HRS-6209 — HRS-6209
  • Drug: HRS-1358 — HRS-1358
Study Locations (2 sites)
Harbin Medical University Affiliated Cancer Hospital, Harbin, Heilongjiang 150081 China
Henan Cancer Hospital, Zhengzhou, Henan 450000 China
Eligibility Criteria
Inclusion Criteria: 1. ECOG physical condition 0-1 point. 2. Advanced unresectable or metastatic breast cancer confirmed by histopathology or cytopathology. 3. Menopausal Status. 4. Previous treatments: (New) adjuvant endocrine therapy combined or not combined with CDK4/6 inhibitors during or within 12 months after treatment, including recurrence/metastasis, shall be counted as one line of endocrine therapy and one line of CDK4/6 inhibitor therapy (such as combined CDK4/6 inhibitors); Relapse/metastasis during (new) adjuvant chemotherapy or within 6 months after the end of treatment (whichever occurs later), counted as one line of chemotherapy. 5. Disease progression confirmed by imaging during or after the last systemic anti-tumor treatment before the first use of medication (limited to the stage of efficacy expansion). 6. There must be at least one measurable extracranial lesion that meets RECIST v1.1 at baseline. 7. Expected survival\>3 months. 8. The functional level of 8 organs is good. 9. Previous treatments: The interval between receiving nitrosourea or mitomycin C before the first medication in this study was ≥ 6 weeks; Receiving cytotoxic drugs, endocrine therapy, immunotherapy, targeted therapy, surgical interval (excluding biopsy or PICC catheterization or PORT infusion port catheterization surgery), or other clinical studies with the last dose of medication ≥ 4 weeks; The interval between the end of radiotherapy is ≥ 2 weeks. 10. female participants with fertility must agree to use efficient contraceptive measures for contraception during the study treatment period and within 7 months after the end of the study treatment period; Female subjects with fertility must have a negative serum HCG test within 7 days prior to enrollment in the study and must be non lactating. 11. Voluntarily participate in this clinical trial, willing and able to comply with the clinical visit and research related procedures, understand the research procedures, and have signed informed consent. Exclusion Criteria: 1. Patients with active (uncontrolled or symptomatic) brain metastases, cancerous meningitis, spinal cord compression, or a history of primary CNS tumors; patients with brain metastases who have completed treatment at least 28 days prior to first use of the study drug and are asymptomatic can be considered for enrollment if they have been confirmed asymptomatic by cranial imaging studies such as CT, MRI, or venography without evidence of cerebral hemorrhage, and have completed treatment at least 28 days before the first use of the study drug. 2. Patients with a history of severe cardiovascular disease, including: (1) Congestive heart failure (NYHA Class\>2); (2) Severe/unstable angina, new angina within the last 3 months; (3) Myocardial ischemia requiring long-term medication control; patients with NYHA Class III-IV heart failure; (4) Acute myocardial infarction within the last 6 months; (5) Any grade 2 or higher supraventricular or ventricular arrhythmia that requires treatment or intervention; (6) Atrial fibrillation, coronary/peripheral artery bypass grafts, or cerebrovascular symptoms including transient ischemic attacks. 3. Patients with factors affecting oral medication intake, such as difficulty swallowing or intestinal obstruction, or have active gastrointestinal diseases or other diseases that may significantly affect drug absorption, distribution, metabolism, or excretion (active inflammatory bowel disease or chronic diarrhea, enterocolitis or upper gastrointestinal surgery, including gastrectomy). 4. Patients with uncontrollable third space effusions (such as large ascites, pleural effusion, pericardial effusion) or cancerous lymphedema. 5. Pregnant women, nursing mothers, or those planning to become pregnant during the study period. 6. Patients with significant liver disease history, untreated active hepatitis B (defined as positivity for HBsAg or HBcAb and HBV-DNA levels above the normal upper limit), or active hepatitis C (defined as HCV-RNA levels above the detection limit). 7. Patients with uncontrolled chronic systemic comorbidities (such as severe chronic lung, liver, kidney or heart diseases). 8. Patients with active autoimmune diseases, history of immune deficiency, autoimmune disease history, or history of diseases or syndromes requiring systemic corticosteroid hormones or immunosuppressive drug therapy, or have acquired (HIV infection) or congenital immunodeficiency diseases, or have a history of organ transplantation (including homologous bone marrow transplantation). 9. Patients with active infectious tuberculosis and need for antimicrobial treatment. 10. Patients with known significant liver disease history, untreated active hepatitis B (defined as positivity for HBsAg or HBcAb and HBV-DNA levels above the normal upper limit), or active hepatitis C (defined as HCV-RNA levels above the detection limit). 11. Patients who have had other malignancies within the past 5 years, except: 1) Completely cured skin basal cell carcinoma and cervical intraepithelial neoplasia; 2) Completely cured and without recurrence of secondary primary cancer within 5 years. 12. Patients who have used strong or moderate inhibitors of CYP3A4 within 1 week before the first dose or strong or moderate inducers of CYP3A4 within 2 weeks before the first dose. 13. Pregnant women, nursing mothers, or those planning to become pregnant during the study period. 14. Patients with a history of neurological or psychiatric disorders, or those with a history of abuse of psychotropic drugs or drug addiction. 15. Patients who are expected to receive other anti-tumor treatments or medications during this study. 16. Patients with other serious physical or laboratory abnormalities that may increase the risk of participating in the study or interfere with study results, and those deemed by the investigator not suitable for participation in this study. 17. Patients with anti-tumor treatment-related toxicity in the past (excluding alopecia; according to the judgment of the investigator, after consultation with the sponsor, some tolerable chronic Grade II toxicities may be excluded). 18. Patients who have an allergy to any study drug or any excipient.
Conditions Breast Cancer Early Stage Breast Cancer ...
Phase PHASE2
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Cancer is currently a leading cause of morbidity and mortality worldwide. Chemotherapeutic agents, despite being effective in arresting the progression of cancer by targeting and eliminating rapidly dividing cancer cells, are associated with various adverse effects. Chemotherapy-induced peripheral neuropathy (CIPN) is a serious clinical adverse effect of certain chemotherapeutic agents. For many patients, CIPN symptoms could be severe, disabling, and significantly impairing the activities of daily living (ADL) and diminishing the quality of life (QoL). Paclitaxel-induced peripheral neuropathy may affect up to 97% of paclitaxel-treated patients and become chronic in more than 60% of cases. The initial symptoms of paclitaxel-induced peripheral neuropathy (PIPN) include numbness, tingling, and allodynia (painful sensations in response to normally non-painful stimuli) that can be manifested in the patient's fingers and toes within 24-72 h post-injection. These symptoms may later progress to affect the patient's lower leg and wrists in a "glove and stocking" pattern. Symptoms typically begin distally and continue proximally as the situation worsens. Memantine is a non-competitive NMDA receptor antagonist that inhibits the prolonged influx of Ca2+, responsible for neuronal excitotoxicity while maintaining the physiological NMDA receptor's function and avoiding psychotropic adverse events. Although memantine has been the main treatment option for moderate and severe Alzheimer's disease in the last two decades, numerous studies have investigated its other potential uses. Some studies showed that memantine diminished chronic pain in complex regional pain syndrome, phantom limb pain, and fibromyalgia. Most in vivo and in vitro studies attributed the neuroprotective effects of memantine to the blockade of NMDA receptors on neurons as well as inhibition of microglia activation with subsequent reduction of pro-inflammatory mediators' production such as extracellular superoxide anion, intracellular ROS, nitric oxide, prostaglandin E2, and TNF-α, and stimulation of neurotrophic factor release from astroglia.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Triple

Interventions / Regimen

  • Drug: Memantine-HCl — Memantine hydrochloride 20 mg once daily for 12 weeks.
  • Drug: Placebo Oral Tablet — A once daily matched tablet of placebo for 12 weeks

Primary Outcomes

  • Incidence and grading of paclitaxel induced peripheral neuropathy (PIPN) (Weekly for 12 weeks.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-10-30
Completion: 2025-10
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ain Shams University
Contact Information
Study Contact:
Mahmoud M Gharib, Assistant lecturer
02 01286584470
dr.mahmoudgharib.mg@gmail.com
Interventions
  • Drug: Memantine-HCl — Memantine hydrochloride 20 mg once daily for 12 weeks.
  • Drug: Placebo Oral Tablet — A once daily matched tablet of placebo for 12 weeks
Study Locations (1 sites)
Ain shams University Hospitals, Cairo, Egypt
Eligibility Criteria
Inclusion Criteria: * Adult patients (\>18 years old). * Patients with confirmed diagnosis of non-metastatic breast cancer planned to receive weekly adjuvant/neo-adjuvant paclitaxel. * Patients with Eastern Cooperative Oncology Group (ECOG) performance (Oken et al., 1982) status of 0-2. Exclusion Criteria: * Patients with pre-existing neuropathic conditions. * Patients with diabetes mellitus. * Patients with a history of seizure disorder. * Patients with renal impairment (creatinine clearance less than 60 ml/min), or hepatic impairment (defined as ALT an AST \> 3 times upper limits of normal) * Patients with inadequate bone marrow functions (defined as absolute neutrophilic count less than 1,500/mm3 or platelets count less than 100,000/mm3). * Concomitant use of vitamin B1, B6, B9, or B12. * Patients receiving medications that possibly induce peripheral neuropathy including amiodarone, colchicine, metronidazole, antimycobacterials, and nucleoside reverse transcriptase inhibitors, and phenytoin (Jones et al., 2020). * Patients receiving gabapentinoids, antidepressants, or opioids. * Pregnancy or lactation. * History of hypersensitivity to memantine.
Conditions Chronic Heart Failure
Phase PHASE4
Enrollment 156
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Effect of Empagliflozin on Quality of Life in patient of Chronic Heart Failure with Diabetes Mellitus Type II. As per ESC Guidelines Empagliflozin is recommended as part of the first-line treatment for HFrEF, irrespective of diabetes status. As per American College of Cardiology (ACC)/American Heart Association (AHA) Empagliflozin is recommended in both diabetic and non-diabetic HF (especially beneficial in patients with HFrEF and HFpEF). The aim of my study is to assess the impact of Empagliflozin on quality of life in Pakistani patients, considering the genetic, environmental and cultural factors. The study will also explore whether Empagliflozin can offer cost-effective option for managing chronic heart failure and diabetes, potentially reducing the economic burden on both patients and health care system.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Empagliflozin 10 MG — participants will be divided in two groups one group will empagliflozin 10mg once daily along with standard treatment secong group receiving placebo once daily along with standard treatment.

Primary Outcomes

  • improvement in Kansas city cardiomyopathy questionnaire scoring (18 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-04-01
Completion: 2026-12-01
Eligibility
Age: 40 Years and older
Sex: ALL
Volunteers: false
Enrollment: 156 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fazaia Ruth Pfau Medical College
Principal Investigators:
  • Tooba Riaz, MBBS (PRINCIPAL_INVESTIGATOR) - Fazaia Ruth Pfau Medical College
Contact Information
Study Contact:
Tooba Riaz, MBBS
03333231665
drtoobariaz@outlook.com
DR Asghar Mehdi, MBBS Phd
03008228284
drasgharmehdi@gmail.com
Dr Masood Ahmed, MBBS Phd
03002922361
principal.frpmc@mail.au.edu.pk
Fazaia Ruth Pfau Hospital
Interventions
  • Drug: Empagliflozin 10 MG — participants will be divided in two groups one group will empagliflozin 10mg once daily along with standard treatment secong group receiving placebo once daily along with standard treatment.
Study Locations (1 sites)
Fazaia Ruth Pfau Hospital, Karachi, Sindh 75120 Pakistan
Eligibility Criteria
Inclusion Criteria: 1. Age 40-70 years at time of screening. 2. Both Men and women are included in study. 3. Patients with chronic heart failure and currently categorized in class II-IV heart failure as per NHYA classification having ejection fraction less than 40%. 4. Patients having NT- proBNP levels greater than 25pg/ml. 5. Diabetic patient diagnosed (HbA1c \> 6.5mg/dl) and currently taking antidiabetic medicine. Exclusion Criteria: 1. Pregnant female. 2. Patient with end stage renal disease (ESRD). 3. Patient with acute decompensated heart failure. 4. Acute coronary syndrome patients.
Conditions Depression
Phase PHASE3
Enrollment 400
Locations 8 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to compare the relative effectiveness, acceptability, and side effects of ketamine delivered through an IV (a drip into the arm) which is not currently FDA approved for use in the treatment of treatment-resistant depression (TRD) and Esketamine (Spravato®), taken as a nasal spray which has received FDA approval for use in the treatment of treatment-resistant depression (TRD) in the treatment of patients with treatment-resistant depression (TRD). The study will look at the following: * How well the treatment helps with symptoms of depression (effectiveness), * How comfortable and willing people are to use the treatment (acceptability), and * How well people can deal with any side effects from the treatment (tolerability). The study will also examine factors that may predict which treatment works better for certain patients.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Racemic ketamine — Ketamine will be given intravenously. Per FDA guidance, the max dose of ketamine will be 60mg per day, with a total lifetime limit of 8 doses. Ketamine will be infused over 40 minutes.
  • Drug: Spravato (Esketamine) — Spravato® (Esketamine) will be given intranasally. For esketamine, the dose will be between 56 and 84mg, according to the FDA label for the drug. Allowances will be made for patients who have difficulty tolerating these doses to be dosed at 28mg in subsequent treatment sessions.

Primary Outcomes

  • Self-Reported Effectiveness (30 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-01-27
Completion: 2030-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Yale University
Collaborators: Patient-Centered Outcomes Research Institute
Principal Investigators:
  • Samuel Wilkinson, MD (PRINCIPAL_INVESTIGATOR) - Samuel.Wilkinson@yale.edu
Contact Information
Study Contact:
Cindy Voghell
203-737-4784
Cynthia.Voghell@yale.edu
Lisa Harding, MD
203-701-9737
Trials@DepressionMD.com
Mood Institute
Lisa Harding, MD
Mood Institute
Interventions
  • Drug: Racemic ketamine — Ketamine will be given intravenously. Per FDA guidance, the max dose of ketamine will be 60mg per day, with a total lifetime limit of 8 doses. Ketamine will be infused over 40 minutes.
  • Drug: Spravato (Esketamine) — Spravato® (Esketamine) will be given intranasally. For esketamine, the dose will be between 56 and 84mg, according to the FDA label for the drug. Allowances will be made for patients who have difficulty tolerating these doses to be dosed at 28mg in subsequent treatment sessions.
Study Locations (8 sites)
Mood Institute, Milford, Connecticut 06461 United States
Yale School of Medicine, New Haven, Connecticut 06512 United States
Emory University, Atlanta, Georgia 30322 United States
University of Michigan, Ann Arbor, Michigan 48104 United States
LifeStance Health, Moore, Oklahoma 73160 United States
Athena Care, Nashville, Tennessee 37228 United States
Houston Center for Advanced Psychiatric Treatment, Bellaire, Texas 77401 United States
Seattle NTC, Seattle, Washington 98104 United States
Eligibility Criteria
Inclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study * Adults ages 18 or older * Diagnosis of major depressive disorder that is refractory to two or more antidepressant trials * Moderate or severe depression based on an initial MADRS score ≥ 25 * Judged appropriate for ketamine or esketamine by clinician, independent of potential study participation * A female participant must be: a. Not of childbearing potential\*, OR b. Of childbearing potential and practicing a highly effective method of contraception (failure rate of \<1% per year when used consistently and correctly) and agrees to remain on a highly effective method while receiving study intervention and until 1 week after last dose - the end of relevant systemic exposure. The investigator will evaluate the potential for contraceptive method failure (e.g., noncompliance, recently initiated) in relationship to the first dose of drug. Acceptable methods of contraception are: i. combined (estrogen and progestogen containing) hormonal or progestogen-only hormonal contraception associated with inhibition of ovulation (oral, transdermal, or intravaginal) ii. intrauterine device (IUD) iii. intrauterine hormone-releasing system (IUS) iv. bilateral tubal occlusion/ligation v. male partner with a bilateral vasectomy with documented aspermia or a bilateral orchiectomy vi. male or female condom with spermicide, diaphragm, or sponge with spermicide (Note: Use of condom as the sole method of contraception is not considered to be a highly effective method of contraception). * A female participant must agree not to donate eggs (ova, oocytes) or freeze for future use for the purposes of assisted reproduction during the study \* We will consider women to be of childbearing potential if they are within 2 years of menopause (within 3 years since last menstrual period) and have not had a hysterectomy, bilateral oophorectomy, or other definitive surgical intervention. Exclusion Criteria: * Diagnosis of bipolar disorder or psychotic disorder (i.e., schizophrenia, schizoaffective disorder) * Other psychiatric comorbidities are permitted so long as depression is the predominant diagnosis * Active or recent (within 12 months) substance use disorder (other than nicotine) * Pregnant or lactating women * Intracerebral hemorrhage or aneurysmal vascular disease * Hypersensitivity to ketamine, esketamine or any of the excipients * Known family history of ketamine use disorder * Prior known ketamine use disorder as well as subjects for whom study participations will result in more than 8 lifetime exposures to ketamine (e.g., prior exposure to ketamine, prior recreational use with ketamine). Prior esketamine exposure is also exclusionary. * Uncontrolled hypertension, as demonstrated by a blood pressure of greater than 145 / 90 at screening visit. (Pre-treatment blood pressure will be permitted to be 150 / 95 to allow for "whitecoat" hypertension on treatment visits 1-8.) * Known cardiovascular and cerebrovascular conditions that are associated with an increased risk related to ketamine or esketamine administration (including space-occupying CNS lesions). This includes those prospective participants who undergo EKG and are shown to have an abnormality that would put them at increased risk related to treatment. * Known condition for which an acute rise in blood pressure would pose a serious risk. * Arteriovenous malformation * Positive urine toxicology at screening visit, except for substances that are prescribed (i.e., benzodiazepines, stimulants). Given the extended length of time between exposure and negative toxicology screen, a positive screen for THC will not be exclusionary unless the pattern of use and clinical evaluation are indicative of cannabis use disorder. Cannabis used within 24 hours of dosing is exclusionary. * Positive alcohol breathalyzer at screening or clinical signs of intoxication * The patient is unable to arrange for someone to drive them home after each treatment session; patients who are unwilling to refrain from driving and operating machinery on treatment days until the next day following sleep will be excluded.
Conditions Major Depressive Disorder, Loneliness
Phase NA
Enrollment 180
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

High loneliness is prevalent among older adults and is a significant risk factor for major depression and low recovery rates in patients. Current interventions for loneliness are limited. Previous research has demonstrated a link between loneliness, negative social emotions, and reduced resting-state functional connectivity in the lateral prefrontal cortex (LPFC) and the default mode network (DMN). Transcranial direct current stimulation (tDCS) has shown promise in enhancing emotional regulation and connectivity, potentially alleviating loneliness in older adults with depression.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Device: Transcranial direct current stimulation (tDCS) on the Left DLPFC — The tDCS parameters were set to a current of 2mA for a single session lasting 20 minutes. For stimulating the lDLPFC, the positive electrode was placed at position F3, and the negative electrode was placed in the right supraorbital area/FP2 (e.g., Dubreuil-Vall et al., 2021, Biol Psychiatry: CNNI).
  • Device: Transcranial direct current stimulation (tDCS) on the right VLPFC — The tDCS parameters were set to a current of 2mA for a single session lasting 20 minutes. Based on the EEG 10-20 international system, the positive electrode for stimulating the rVLPFC was placed at position F6, while the negative electrode was placed in the left supraorbital area/FP1 (e.g., He et al., 2020, Psychol Med)
  • Device: Sham stimulation group — The electrode positions were randomized to match those of the rVLPFC or lDLPFC groups, but the stimulation only lasted for the first 30 seconds.

Primary Outcomes

  • Change in loneliness levels from baseline measured by the UCLA Loneliness Scale from baseline (2 weeks, 1.5 months and 3.5 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-10-29
Completion: 2026-12-30
Eligibility
Age: 60 Years and older
Sex: ALL
Volunteers: true
Enrollment: 180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Guangzhou Psychiatric Hospital
Collaborators: The University of Hong Kong
Contact Information
Study Contact:
Kangguang Lin, PhD; MD
8613560360144
klin@gzhmu.edu.cn
Robin Shao, PhD
James0828@hotmail.com
Kangguang Lin, Ph.D; MD
8602081268219
linkangguang@163.com
Guangzhou Brain Hospital
Interventions
  • Device: Transcranial direct current stimulation (tDCS) on the Left DLPFC — The tDCS parameters were set to a current of 2mA for a single session lasting 20 minutes. For stimulating the lDLPFC, the positive electrode was placed at position F3, and the negative electrode was placed in the right supraorbital area/FP2 (e.g., Dubreuil-Vall et al., 2021, Biol Psychiatry: CNNI).
  • Device: Transcranial direct current stimulation (tDCS) on the right VLPFC — The tDCS parameters were set to a current of 2mA for a single session lasting 20 minutes. Based on the EEG 10-20 international system, the positive electrode for stimulating the rVLPFC was placed at position F6, while the negative electrode was placed in the left supraorbital area/FP1 (e.g., He et al., 2020, Psychol Med)
  • Device: Sham stimulation group — The electrode positions were randomized to match those of the rVLPFC or lDLPFC groups, but the stimulation only lasted for the first 30 seconds.
Study Locations (1 sites)
Guangzhou Brain Hospital, Guangzhou, Guangdong 510370 China
Eligibility Criteria
Inclusion Criteria: * High loneliness (UCLA Loneliness Scale \> 43). * Diagnosis of major depressive disorder confirmed by the Structured Clinical Interview for DSM-5 Disorders. * absence of suicidal ideation (Hamilton Depression Scale item 3 score ≤ 1). Exclusion Criteria: * Severe neurological diseases. * Bipolar disorder, schizophrenia, addiction, or impulse control disorders. * Contraindications for tDCS or MRI (e.g., metal implants). * Presence of suicidal ideation.
Conditions Asthma in Children, Depression
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to test the effectiveness and implementation of delivering Enhanced Brief Interpersonal Psychotherapy (IPT-B), an evidence-based maternal depression treatment, to mothers of children under the age of 18 in an urban pediatric asthma clinic. Researchers will compare Enhanced IPT-B and supplemented usual care (brief care coordination). The main questions the trial aims to answer are: 1. Does Enhanced IPT-B decrease maternal depressive symptoms? 2. Does Enhanced IPT-B improve child asthma management and health outcomes (exacerbations, symptoms, control)? 3. What are the preliminary implementation outcomes of delivering Enhanced IPT-B in an urban pediatric asthma clinic?

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Enhanced Brief Interpersonal Psychotherapy — Enhanced IPT-B consists of a single, 45-60-minute pre-treatment engagement session followed by eight weekly, 45-minute individual sessions carried out within an 8-12-week timeframe.
  • Behavioral: Supplemented Usual Care — Usual care for caregivers with depressive symptoms involves the asthma clinic physician discussing the PHQ-9 results with the caregiver, providing brief psychoeducation on depression and giving the caregiver a written list of mental health resources. Usual care will be supplemented by providing short-term care coordination. Care coordination will involve assisting the participant in calling a mental health clinic to make an appointment and one follow-up phone call within two weeks.

Primary Outcomes

  • Maternal depressive symptoms (T2 (3 months post-baseline))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-10-15
Completion: 2027-03-15
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Children's National Research Institute
Collaborators: National Institute on Minority Health and Health Disparities (NIMHD)
Principal Investigators:
  • Rachel Margolis, PhD, MSW (PRINCIPAL_INVESTIGATOR) - Children's National Research Institute
Contact Information
Study Contact:
Geraldine Mendez-Gonzalez
(202) 476-6956
GMENDEZGON@childrensnational.org
Geraldine Mendez-Gonzalez
202-476-6956
GMENDEZGON@childrensnational.org
Children's National Hospital
Rachel Margolis, PhD, MSW
Children's National Hospital
Interventions
  • Behavioral: Enhanced Brief Interpersonal Psychotherapy — Enhanced IPT-B consists of a single, 45-60-minute pre-treatment engagement session followed by eight weekly, 45-minute individual sessions carried out within an 8-12-week timeframe.
  • Behavioral: Supplemented Usual Care — Usual care for caregivers with depressive symptoms involves the asthma clinic physician discussing the PHQ-9 results with the caregiver, providing brief psychoeducation on depression and giving the caregiver a written list of mental health resources. Usual care will be supplemented by providing short-term care coordination. Care coordination will involve assisting the participant in calling a mental health clinic to make an appointment and one follow-up phone call within two weeks.
Study Locations (1 sites)
Children's National Hospital, Washington D.C., District of Columbia 20010 United States
Eligibility Criteria
Inclusion Criteria: Maternal: * Primary caregiver of the child with asthma seen at the community-based asthma clinic * Female (self-identified) * Black (self-identified) * ≥ 18 years of age * English-speaking * PHQ-9 ≥ 8 during standardized screening at the child with asthma's clinic visit Child: * \<18 years old for the duration of the 6-month study period * Publicly insured * Physician-diagnosed persistent asthma Exclusion Criteria: Maternal: * Acutely suicidal (high risk on the C-SSRS at child's asthma clinic visit) * Bipolar disorder or mania * Schizophrenia * Current substance abuse/dependence * Current serious physical intimate partner violence (IPV) * Lack of capacity to meaningfully participate in study procedures, as assessed by study staff during screening Child: * Significant medical co-morbidity (e.g., disorders of the cardiorespiratory system, significant developmental delay, diabetes, seizure disorder, and sickle cell disease) * Enrolled in another intervention with a behavioral component and/or novel asthma therapeutics